Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.

Sharon J. B. Hanley; Hiromasa Fujita; Satomi Aoyama-Kikawa; Mitsunori Kasamo; Toshihiko Torigoe; Yoshihiro Matsuno; Sakuragi Noriaki; COMPACT Study Group

doi:10.3802/jgo.2021.32.e86

Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.

Sharon J. B. Hanley^* (Corresponding Author), Hiromasa Fujita, Satomi Aoyama-Kikawa, Mitsunori Kasamo, Toshihiko Torigoe, Yoshihiro Matsuno, Sakuragi Noriaki, COMPACT Study Group

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

2 Downloads (Pure)

Abstract

OBJECTIVE: While cytology-based screening programs have significantly reduced mortality and morbidity from cervical cancer, the global consensus is that primary human papillomavirus (HPV) testing increases detection of high-grade cervical intraepithelial neoplasia (CIN) and invasive cancer. However, the optimal triage strategy for HPV+ women to avoid over-referral to colposcopy may be setting specific. We compared absolute and relative risk (RR) of >CIN2/3 within 12 months of a negative cytologic result in women HPV16/18+ compared to those with a 12-other high-risk HPV (hrHPV) genotype to identify women at greatest risk of high-grade disease and permit less aggressive management of women with other hrHPV infections. METHODS: Participants were 14,160 women aged 25-69 years with negative cytology participating in the COMparison of HPV genotyping And Cytology Triage (COMPACT) study. Women who were HPV16/18+ were referred to colposcopy. Those with a 12-other hrHPV type underwent repeat cytology after 6 months and those with >abnormal squamous cells of undetermined significance went to colposcopy. RESULTS: Absolute risk of >CIN2 in HPV16/18+ women was 19.5% (95% CI=12.4%-29.4%). In women 25-29 years and HPV16+ it was 40.0% (95% CI=11.8%-76.9%). Absolute risk of >CIN3 in women HPV16/18+ was 11.0% (95% CI=5.9%-19.6%). For women 30-39 years and HPV16+ it was 23.1% (95% CI=5.0%-53.8%). Overall risk of >CIN2, >CIN3 in women with a 12-other hrHPV HPV type was 5.6% (95% CI=3.1%-10.0%) and 3.4% (95% CI=1.6%-7.2%) respectively. RR of >CIN2, >CIN3 in HPV16/18+ vs. 12-other hrHPV was 3.5 (95% CI=1.7-7.3) and 3.3 (95% CI=1.2-8.8), respectively. CONCLUSION: Primary HPV screening with HPV16/18 partial genotyping is a promising strategy to identify women at current/future risk of >CIN2 in Japan without over-referral to colposcopy. TRIAL REGISTRATION: Trial Registration: UMIN Clinical Trials Registry Identifier: UMIN000013203.

Original language	English
Pages (from-to)	e86
Number of pages	14
Journal	J Gynecol Oncol
Volume	32
Issue number	6
Early online date	13 Sept 2021
DOIs	https://doi.org/10.3802/jgo.2021.32.e86
Publication status	Published - 1 Nov 2021
Event	IPVC 2018: 32nd International Papillomavirus conference - Sidney, Australia Duration: 2 Jun 2018 → 6 Jun 2018 https://ipvc2018.org/

Bibliographical note

ACKNOWLEDGEMENTS
COMPACT Study Group: Kokichi Kikuchi, Akiko Tamakoshi, Takayuki Sasaki, Motoki Matsuura, Yasuhito Kato, Hidemichi Watari, Tsuyoshi Saito, Kazuo Sengoku. The authors would like to thank all the women who participated in the study.

Keywords

Female
Humans
Early Detection of Cancer
Pregnancy
*Papillomavirus Infections/diagnosis
*Uterine Cervical Neoplasms/diagnosis
Cancer Screening
Cervical Cancer
Colposcopy
Cytology
Genotype
Human Papillomavirus
Human papillomavirus 16/genetics
Human papillomavirus 18/genetics
Triage

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3802/jgo.2021.32.e86Licence: CC BY-NC

Hanley_etalJGO_Evaluation_Of_Partial_VoR
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Final published version, 1.96 MBLicence: CC BY-NC

Cite this

@article{6357ecd9b86f4a00b217294433797585,

title = "Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.",

abstract = "OBJECTIVE: While cytology-based screening programs have significantly reduced mortality and morbidity from cervical cancer, the global consensus is that primary human papillomavirus (HPV) testing increases detection of high-grade cervical intraepithelial neoplasia (CIN) and invasive cancer. However, the optimal triage strategy for HPV+ women to avoid over-referral to colposcopy may be setting specific. We compared absolute and relative risk (RR) of >CIN2/3 within 12 months of a negative cytologic result in women HPV16/18+ compared to those with a 12-other high-risk HPV (hrHPV) genotype to identify women at greatest risk of high-grade disease and permit less aggressive management of women with other hrHPV infections. METHODS: Participants were 14,160 women aged 25-69 years with negative cytology participating in the COMparison of HPV genotyping And Cytology Triage (COMPACT) study. Women who were HPV16/18+ were referred to colposcopy. Those with a 12-other hrHPV type underwent repeat cytology after 6 months and those with >abnormal squamous cells of undetermined significance went to colposcopy. RESULTS: Absolute risk of >CIN2 in HPV16/18+ women was 19.5% (95% CI=12.4%-29.4%). In women 25-29 years and HPV16+ it was 40.0% (95% CI=11.8%-76.9%). Absolute risk of >CIN3 in women HPV16/18+ was 11.0% (95% CI=5.9%-19.6%). For women 30-39 years and HPV16+ it was 23.1% (95% CI=5.0%-53.8%). Overall risk of >CIN2, >CIN3 in women with a 12-other hrHPV HPV type was 5.6% (95% CI=3.1%-10.0%) and 3.4% (95% CI=1.6%-7.2%) respectively. RR of >CIN2, >CIN3 in HPV16/18+ vs. 12-other hrHPV was 3.5 (95% CI=1.7-7.3) and 3.3 (95% CI=1.2-8.8), respectively. CONCLUSION: Primary HPV screening with HPV16/18 partial genotyping is a promising strategy to identify women at current/future risk of >CIN2 in Japan without over-referral to colposcopy. TRIAL REGISTRATION: Trial Registration: UMIN Clinical Trials Registry Identifier: UMIN000013203.",

keywords = "Female, Humans, Early Detection of Cancer, Pregnancy, *Papillomavirus Infections/diagnosis, *Uterine Cervical Neoplasms/diagnosis, Cancer Screening, Cervical Cancer, Colposcopy, Cytology, Genotype, Human Papillomavirus, Human papillomavirus 16/genetics, Human papillomavirus 18/genetics, Triage",

author = "Hanley, {Sharon J. B.} and Hiromasa Fujita and Satomi Aoyama-Kikawa and Mitsunori Kasamo and Toshihiko Torigoe and Yoshihiro Matsuno and Sakuragi Noriaki and {COMPACT Study Group}",

note = "ACKNOWLEDGEMENTS COMPACT Study Group: Kokichi Kikuchi, Akiko Tamakoshi, Takayuki Sasaki, Motoki Matsuura, Yasuhito Kato, Hidemichi Watari, Tsuyoshi Saito, Kazuo Sengoku. The authors would like to thank all the women who participated in the study. ; IPVC 2018 : 32nd International Papillomavirus conference, IPVC ; Conference date: 02-06-2018 Through 06-06-2018",

year = "2021",

month = nov,

day = "1",

doi = "10.3802/jgo.2021.32.e86",

language = "English",

volume = "32",

pages = "e86",

journal = "J Gynecol Oncol",

issn = "2005-0399",

publisher = "Korean Society of Gynecologic Oncology and Colposcopy",

number = "6",

url = "https://ipvc2018.org/",

}

TY - JOUR

T1 - Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.

AU - Hanley, Sharon J. B.

AU - Fujita, Hiromasa

AU - Aoyama-Kikawa, Satomi

AU - Kasamo, Mitsunori

AU - Torigoe, Toshihiko

AU - Matsuno, Yoshihiro

AU - Noriaki, Sakuragi

AU - COMPACT Study Group

N1 - ACKNOWLEDGEMENTS COMPACT Study Group: Kokichi Kikuchi, Akiko Tamakoshi, Takayuki Sasaki, Motoki Matsuura, Yasuhito Kato, Hidemichi Watari, Tsuyoshi Saito, Kazuo Sengoku. The authors would like to thank all the women who participated in the study.

PY - 2021/11/1

Y1 - 2021/11/1

N2 - OBJECTIVE: While cytology-based screening programs have significantly reduced mortality and morbidity from cervical cancer, the global consensus is that primary human papillomavirus (HPV) testing increases detection of high-grade cervical intraepithelial neoplasia (CIN) and invasive cancer. However, the optimal triage strategy for HPV+ women to avoid over-referral to colposcopy may be setting specific. We compared absolute and relative risk (RR) of >CIN2/3 within 12 months of a negative cytologic result in women HPV16/18+ compared to those with a 12-other high-risk HPV (hrHPV) genotype to identify women at greatest risk of high-grade disease and permit less aggressive management of women with other hrHPV infections. METHODS: Participants were 14,160 women aged 25-69 years with negative cytology participating in the COMparison of HPV genotyping And Cytology Triage (COMPACT) study. Women who were HPV16/18+ were referred to colposcopy. Those with a 12-other hrHPV type underwent repeat cytology after 6 months and those with >abnormal squamous cells of undetermined significance went to colposcopy. RESULTS: Absolute risk of >CIN2 in HPV16/18+ women was 19.5% (95% CI=12.4%-29.4%). In women 25-29 years and HPV16+ it was 40.0% (95% CI=11.8%-76.9%). Absolute risk of >CIN3 in women HPV16/18+ was 11.0% (95% CI=5.9%-19.6%). For women 30-39 years and HPV16+ it was 23.1% (95% CI=5.0%-53.8%). Overall risk of >CIN2, >CIN3 in women with a 12-other hrHPV HPV type was 5.6% (95% CI=3.1%-10.0%) and 3.4% (95% CI=1.6%-7.2%) respectively. RR of >CIN2, >CIN3 in HPV16/18+ vs. 12-other hrHPV was 3.5 (95% CI=1.7-7.3) and 3.3 (95% CI=1.2-8.8), respectively. CONCLUSION: Primary HPV screening with HPV16/18 partial genotyping is a promising strategy to identify women at current/future risk of >CIN2 in Japan without over-referral to colposcopy. TRIAL REGISTRATION: Trial Registration: UMIN Clinical Trials Registry Identifier: UMIN000013203.

AB - OBJECTIVE: While cytology-based screening programs have significantly reduced mortality and morbidity from cervical cancer, the global consensus is that primary human papillomavirus (HPV) testing increases detection of high-grade cervical intraepithelial neoplasia (CIN) and invasive cancer. However, the optimal triage strategy for HPV+ women to avoid over-referral to colposcopy may be setting specific. We compared absolute and relative risk (RR) of >CIN2/3 within 12 months of a negative cytologic result in women HPV16/18+ compared to those with a 12-other high-risk HPV (hrHPV) genotype to identify women at greatest risk of high-grade disease and permit less aggressive management of women with other hrHPV infections. METHODS: Participants were 14,160 women aged 25-69 years with negative cytology participating in the COMparison of HPV genotyping And Cytology Triage (COMPACT) study. Women who were HPV16/18+ were referred to colposcopy. Those with a 12-other hrHPV type underwent repeat cytology after 6 months and those with >abnormal squamous cells of undetermined significance went to colposcopy. RESULTS: Absolute risk of >CIN2 in HPV16/18+ women was 19.5% (95% CI=12.4%-29.4%). In women 25-29 years and HPV16+ it was 40.0% (95% CI=11.8%-76.9%). Absolute risk of >CIN3 in women HPV16/18+ was 11.0% (95% CI=5.9%-19.6%). For women 30-39 years and HPV16+ it was 23.1% (95% CI=5.0%-53.8%). Overall risk of >CIN2, >CIN3 in women with a 12-other hrHPV HPV type was 5.6% (95% CI=3.1%-10.0%) and 3.4% (95% CI=1.6%-7.2%) respectively. RR of >CIN2, >CIN3 in HPV16/18+ vs. 12-other hrHPV was 3.5 (95% CI=1.7-7.3) and 3.3 (95% CI=1.2-8.8), respectively. CONCLUSION: Primary HPV screening with HPV16/18 partial genotyping is a promising strategy to identify women at current/future risk of >CIN2 in Japan without over-referral to colposcopy. TRIAL REGISTRATION: Trial Registration: UMIN Clinical Trials Registry Identifier: UMIN000013203.

KW - Female

KW - Humans

KW - Early Detection of Cancer

KW - Pregnancy

KW - Papillomavirus Infections/diagnosis

KW - Uterine Cervical Neoplasms/diagnosis

KW - Cancer Screening

KW - Cervical Cancer

KW - Colposcopy

KW - Cytology

KW - Genotype

KW - Human Papillomavirus

KW - Human papillomavirus 16/genetics

KW - Human papillomavirus 18/genetics

KW - Triage

U2 - 10.3802/jgo.2021.32.e86

DO - 10.3802/jgo.2021.32.e86

M3 - Article

SN - 2005-0399

VL - 32

SP - e86

JO - J Gynecol Oncol

JF - J Gynecol Oncol

IS - 6

T2 - IPVC 2018

Y2 - 2 June 2018 through 6 June 2018

ER -

Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study.

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this